Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension

Giuseppe Derosa, Arrigo E G Cicero, Antonio Gaddi, Amedeo Mugellini, Leonardina Ciccarelli, Roberta Fogari

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The objective of this trial was to compare the metabolic effects of long-term treatment with doxazosin to those of irbesartan in patients with type 2 diabetes and hypertension. We evaluated 96 hypertensive diabetic patients who were randomized to 12 months of double-blind treatment with doxazosin 4 mg/d or irbesartan 300 mg/d. At the end of the study, systolic and diastolic blood pressure (SBP and DBP) were significantly reduced from 152 to 140 mm Hg and from 97 to 87 mm Hg, respectively, with doxazosin (P <0.01). SBP and DBP were reduced from 150 to 134 mm Hg and from 94 to 83 mm Hg, respectively, with irbesartan (P <0.01). Irbesartan had significantly better antihypertensive efficacy than doxazosin (P <0.05). Doxazosin had the greatest effect on glucose metabolism and lipid parameters, with significant (P ≤ 0.05) reductions observed at study end compared with baseline in glycosylated hemoglobin, fasting plasma glucose, fasting plasma insulin, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, and Homeostasis Model Assessment Index. In conclusion, both doxazosin and irbesartan reduced BP during long-term treatment, but not to recommended levels, and doxazosin had the more beneficial effect on glucose metabolism and lipid profile.

Original languageEnglish
Pages (from-to)599-604
Number of pages6
JournalJournal of Cardiovascular Pharmacology
Volume45
Issue number6
DOIs
Publication statusPublished - Jun 2005

Fingerprint

irbesartan
Doxazosin
Type 2 Diabetes Mellitus
Blood Pressure
Hypertension
Lipid Metabolism
Glucose
Fasting
Glycosylated Hemoglobin A
LDL Cholesterol
HDL Cholesterol
Antihypertensive Agents
Triglycerides

Keywords

  • Diabetes mellitus
  • Hypertension
  • Insulin sensitivity
  • Lipids

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. / Derosa, Giuseppe; Cicero, Arrigo E G; Gaddi, Antonio; Mugellini, Amedeo; Ciccarelli, Leonardina; Fogari, Roberta.

In: Journal of Cardiovascular Pharmacology, Vol. 45, No. 6, 06.2005, p. 599-604.

Research output: Contribution to journalArticle

@article{5d7aa5824791499382f57e0f2cc13695,
title = "Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension",
abstract = "The objective of this trial was to compare the metabolic effects of long-term treatment with doxazosin to those of irbesartan in patients with type 2 diabetes and hypertension. We evaluated 96 hypertensive diabetic patients who were randomized to 12 months of double-blind treatment with doxazosin 4 mg/d or irbesartan 300 mg/d. At the end of the study, systolic and diastolic blood pressure (SBP and DBP) were significantly reduced from 152 to 140 mm Hg and from 97 to 87 mm Hg, respectively, with doxazosin (P <0.01). SBP and DBP were reduced from 150 to 134 mm Hg and from 94 to 83 mm Hg, respectively, with irbesartan (P <0.01). Irbesartan had significantly better antihypertensive efficacy than doxazosin (P <0.05). Doxazosin had the greatest effect on glucose metabolism and lipid parameters, with significant (P ≤ 0.05) reductions observed at study end compared with baseline in glycosylated hemoglobin, fasting plasma glucose, fasting plasma insulin, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, and Homeostasis Model Assessment Index. In conclusion, both doxazosin and irbesartan reduced BP during long-term treatment, but not to recommended levels, and doxazosin had the more beneficial effect on glucose metabolism and lipid profile.",
keywords = "Diabetes mellitus, Hypertension, Insulin sensitivity, Lipids",
author = "Giuseppe Derosa and Cicero, {Arrigo E G} and Antonio Gaddi and Amedeo Mugellini and Leonardina Ciccarelli and Roberta Fogari",
year = "2005",
month = "6",
doi = "10.1097/01.fjc.0000161403.91456.39",
language = "English",
volume = "45",
pages = "599--604",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension

AU - Derosa, Giuseppe

AU - Cicero, Arrigo E G

AU - Gaddi, Antonio

AU - Mugellini, Amedeo

AU - Ciccarelli, Leonardina

AU - Fogari, Roberta

PY - 2005/6

Y1 - 2005/6

N2 - The objective of this trial was to compare the metabolic effects of long-term treatment with doxazosin to those of irbesartan in patients with type 2 diabetes and hypertension. We evaluated 96 hypertensive diabetic patients who were randomized to 12 months of double-blind treatment with doxazosin 4 mg/d or irbesartan 300 mg/d. At the end of the study, systolic and diastolic blood pressure (SBP and DBP) were significantly reduced from 152 to 140 mm Hg and from 97 to 87 mm Hg, respectively, with doxazosin (P <0.01). SBP and DBP were reduced from 150 to 134 mm Hg and from 94 to 83 mm Hg, respectively, with irbesartan (P <0.01). Irbesartan had significantly better antihypertensive efficacy than doxazosin (P <0.05). Doxazosin had the greatest effect on glucose metabolism and lipid parameters, with significant (P ≤ 0.05) reductions observed at study end compared with baseline in glycosylated hemoglobin, fasting plasma glucose, fasting plasma insulin, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, and Homeostasis Model Assessment Index. In conclusion, both doxazosin and irbesartan reduced BP during long-term treatment, but not to recommended levels, and doxazosin had the more beneficial effect on glucose metabolism and lipid profile.

AB - The objective of this trial was to compare the metabolic effects of long-term treatment with doxazosin to those of irbesartan in patients with type 2 diabetes and hypertension. We evaluated 96 hypertensive diabetic patients who were randomized to 12 months of double-blind treatment with doxazosin 4 mg/d or irbesartan 300 mg/d. At the end of the study, systolic and diastolic blood pressure (SBP and DBP) were significantly reduced from 152 to 140 mm Hg and from 97 to 87 mm Hg, respectively, with doxazosin (P <0.01). SBP and DBP were reduced from 150 to 134 mm Hg and from 94 to 83 mm Hg, respectively, with irbesartan (P <0.01). Irbesartan had significantly better antihypertensive efficacy than doxazosin (P <0.05). Doxazosin had the greatest effect on glucose metabolism and lipid parameters, with significant (P ≤ 0.05) reductions observed at study end compared with baseline in glycosylated hemoglobin, fasting plasma glucose, fasting plasma insulin, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, and Homeostasis Model Assessment Index. In conclusion, both doxazosin and irbesartan reduced BP during long-term treatment, but not to recommended levels, and doxazosin had the more beneficial effect on glucose metabolism and lipid profile.

KW - Diabetes mellitus

KW - Hypertension

KW - Insulin sensitivity

KW - Lipids

UR - http://www.scopus.com/inward/record.url?scp=19544362031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19544362031&partnerID=8YFLogxK

U2 - 10.1097/01.fjc.0000161403.91456.39

DO - 10.1097/01.fjc.0000161403.91456.39

M3 - Article

VL - 45

SP - 599

EP - 604

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 6

ER -